This trial will test whether using a continuous glucose monitoring system (CGMS) can help improve glycemic control and reduce risks of adverse pregnancy outcomes in gestational diabetes mellitus (GDM) patients, compared to traditional self-monitored blood glucose (SMBG) use.
1 Primary · 6 Secondary · Reporting Duration: at time of delivery
100 Total Participants · 2 Treatment Groups
Primary Treatment: real time continuous glucose monitor · No Placebo Group · N/A
Age 18 - 45 · Female Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: